Timing the initiation of treatment in Parkinson's disease.
Grosset
Donald G
DG
Institute of Neurological Sciences, Department of Neurology, Southern General Hospital, 1345 Govan Rd, Glasgow G51 4TF, UK. d.grosset@clinmed.gla.ac.uk
Schapira
Anthony H
AH
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001479:Basal Ganglia / Q000187:drug effects / Q000503:physiopathology; D018450:Disease Progression; D004298:Dopamine / Q000378:metabolism; D004334:Drug Administration Schedule; D042241:Early Diagnosis; D006801:Humans; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment
D000978:Antiparkinson Agents; D004298:Dopamine